Loading…
Candel Therapeutics, Inc. is projected to rise to $9.00 by 2027, a +12% move from its current price of $8.05. CADL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $7.73 | $8.06 | $8.39 | +0.07% |
| May 30 | $7.61 | $8.06 | $8.54 | +0.14% |
| May 31 | $7.52 | $8.07 | $8.66 | +0.22% |
| Jun 1 | $7.44 | $8.07 | $8.76 | +0.29% |
| Jun 2 | $7.37 | $8.08 | $8.85 | +0.36% |
| Jun 3 | $7.32 | $8.08 | $8.93 | +0.43% |
| Jun 4 | $7.26 | $8.09 | $9.01 | +0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.26 | $8.09 | $9.01 | +0.51% |
| Week 2 | $6.98 | $8.13 | $9.47 | +1.01% |
| Week 3 | $6.78 | $8.17 | $9.85 | +1.53% |
| Week 4 | $6.62 | $8.21 | $10.19 | +2.04% |
| Week 5 | $6.49 | $8.26 | $10.51 | +2.55% |
| Week 6 | $6.37 | $8.30 | $10.81 | +3.07% |
| Week 7 | $6.27 | $8.34 | $11.10 | +3.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company that develops immunotherapies for cancer patients. It advances CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer and for non-small cell lung cancer (NSCLC).
The company also develops CAN-3110, in Phase Ib trials for recurrent high-grade glioma, and it operates the enLIGHTEN Discovery Platform, a herpes simplex virus based discovery platform to create new viral immunotherapy candidates for solid tumors.
The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics was incorporated in 2003 and is headquartered in Needham, Massachusetts.
CADL is the stock ticker for Candel Therapeutics, Inc. The asset trades at $7.99 and has a market capitalization of $585.43M, ranking 2928th by market cap.
The forecast shows a mixed near-term picture with longer-term upside. In 2026 the average price is $7.99 with neutral sentiment, and by 2030 the average price rises to $11.65 with bullish sentiment by 2031 and beyond. By 2050 the forecast average price reaches $52.81 and the max $119.16.
A major floor 55.4% below — a decisive break under it would weaken the trend.
The nearest floor, 36.0% below — buyers have tended to step in here.
The nearest ceiling, 11.1% above — a clean break opens room to run.
A major ceiling 38.8% above — clearing it would confirm fresh momentum.
Key CADL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CADL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.93 | Buy | $8.00 | Buy |
| MA 10 | $8.18 | Sell | $8.01 | Buy |
| MA 20 | $7.86 | Buy | $7.73 | Buy |
| MA 50 | $6.40 | Buy | $6.87 | Buy |
| MA 100 | $5.98 | Buy | $6.29 | Buy |
| MA 200 | $5.69 | Buy | $5.98 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.51 | Neutral |
| Stoch RSI (14) | 18.49 | Buy |
| CCI (20) | 21.54 | Neutral |
| Williams %R (14) | -69.53 | Info |
| MACD (12,26,9) | -0.12 | Sell |
| ROC (12) | -3.59 | Sell |
| Bollinger %B (20,2) | 0.56 | Neutral |
| Stochastic %K (14) | 30.47 | Neutral |
| TRIX (15) | 1.32 | Buy |
| Awesome (5,34) | 0.84 | Buy |
| Ultimate (7,14,28) | 41.18 | Neutral |
| Momentum (10) | -0.67 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 7.91 | Buy |
| ADX (14) | 27.98 | Buy |
| ATR (14) | 0.23 | Info |
The current tone is bullish with an RSI14 of 60, and the near-term trend is supported by a 50-day simple moving average of $6.27 and a 200-day simple moving average of $5.67, signaling a constructive setup.
Key support and resistance are at $4.87 and $8.94 respectively, framing the immediate picture.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.48 | $8.05 | $11.57 | 0% | Neutral | |
| $6.80 | $9.00 | $12.80 | +12% | Neutral | |
| $7.98 | $11.04 | $16.50 | +37% | Bullish | |
| $7.48 | $10.72 | $16.67 | +33% | Bullish | |
| $8.43 | $12.49 | $20.06 | +55% | Bullish | |
| $11.40 | $17.40 | $28.74 | +116% | Bullish | |
| $12.12 | $19.04 | $32.25 | +137% | Bullish | |
| $13.09 | $21.14 | $36.64 | +163% | Bullish | |
| $12.91 | $21.40 | $37.88 | +166% | Bullish | |
| $11.94 | $20.30 | $36.62 | +152% | Bullish | |
| $19.94 | $38.17 | $74.60 | +374% | Bullish | |
| $27.48 | $61.07 | $133.81 | +659% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.48 | $8.05 | $9.47 | +0.00% |
| June 2026 | $6.82 | $8.10 | $9.91 | +0.64% |
| July 2026 | $7.15 | $8.60 | $10.72 | +6.12% |
| August 2026 | $7.15 | $8.69 | $11.00 | +1.05% |
| September 2026 | $6.93 | $8.49 | $10.88 | -2.26% |
| October 2026 | $7.07 | $8.72 | $11.31 | +2.75% |
| November 2026 | $7.24 | $8.99 | $11.77 | +3.11% |
| December 2026 | $7.01 | $8.76 | $11.57 | -2.58% |
Click any year to see its month-by-month CADL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CADL is projected to trade between $4.48 and $11.57, averaging $8.05 — a potential gain of 0% from today's $8.05. A consolidation phase looks the most probable path here.
Candel Therapeutics, Inc.'s 2027 outlook centres on $9.00, within a $6.80 to $12.80 range. That is up +12% on the projected 2026 average. That marks a +12% change versus current levels. Price action looks broadly range-bound.
By 2028, CADL could reach as high as $16.50, with a base case around $11.04 and support toward $7.98 — roughly +37% from $8.05. Buyers look set to stay in control over this stretch.
Expect CADL to range from $7.48 to $16.67 through 2029. The $10.72 average target implies a +33% move from current prices. That is -3% versus the projected 2028 average. Momentum favours further upside here.
The CADL price prediction for 2030 points to an average of $12.49 (low $8.43, high $20.06) — a potential gain of +55% on today's $8.05. Buyers look set to stay in control over this stretch.
In 2031, CADL is projected to trade between $11.40 and $28.74, averaging $17.40 — a potential gain of +116% from today's $8.05. That is up +39% on the projected 2030 average. Momentum favours further upside here.
Candel Therapeutics, Inc.'s 2032 outlook centres on $19.04, within a $12.12 to $32.25 range. That is up +9% on the projected 2031 average. That marks a +137% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CADL could reach as high as $36.64, with a base case around $21.14 and support toward $13.09 — roughly +163% from $8.05. Momentum favours further upside here.
Expect CADL to range from $12.91 to $37.88 through 2034. The $21.40 average target implies a +166% move from current prices. That is up +1% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The CADL price prediction for 2035 points to an average of $20.30 (low $11.94, high $36.62) — a potential gain of +152% on today's $8.05. Momentum favours further upside here.
In 2040, CADL is projected to trade between $19.94 and $74.60, averaging $38.17 — a potential gain of +374% from today's $8.05. That is up +88% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Candel Therapeutics, Inc.'s 2050 outlook centres on $61.07, within a $27.48 to $133.81 range. That is up +60% on the projected 2040 average. That marks a +659% change versus current levels. Momentum favours further upside here.
Investing $1,000 in CADL today (≈ 124.223602 CADL) could be worth
$7,586.64
+$6,586.64 (+659%) by 2050 · US Dollar
Based on the average projected CADL price of $61.07 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CADLwould be worth at today's price.
$1,000 invested in CADL on May 27, 2025 (≈ 178.571432 CADL) would be worth
$1,437.5
+$437.5 (+43.8%) today · 1.44× · US Dollar
Based on a CADL entry price of $5.6 vs. today's $8.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.71 | $1,044.1 | +4.4% |
| 1 month ago | $6.29 | $1,279.81 | +28.0% |
| 3 months ago | $5.15 | $1,563.11 | +56.3% |
| 6 months ago | $4.77 | $1,687.63 | +68.8% |
| 1 year ago | $5.6 | $1,437.5 | +43.8% |
| All time (4.8y) ago | $7 | $1,150 | +15.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CADL forecast.
Our base-case forecast reaches $16.00 around 2031.
Implied market cap at $16.00: $1.17B
Looking across the multi-year forecast, 2026 shows a neutral outlook with an average price of $7.99 and a range from $4.48 to $11.45 (max). The 2027 forecast is neutral with an average of $8.79 and a max of $12.66, implying a 10% ROI in that year.
From 2028 onward, the model projects continued upside: 2028 avg $10.66 (33.4% ROI), 2029 avg $10.01 (25.3%), and 2030 avg $11.65 (45.8%). The 2031–2035 window remains bullish, with 2031 avg $16.36 (104.8%), 2032 $17.71 (121.6%), 2033 $19.73 (147%), 2034 $19.73 (146.9%), and 2035 $18.28 (128.8%).
Longer term, 2040 shows an average of $34.50 (331.8% ROI) and 2050 an average of $52.81 (561% ROI), with max values of $69.16 in 2040 and $119.16 in 2050. All these years carry a bullish sentiment in the forecast. These are estimates, not guarantees, and depend on many factors.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $7.72, an average of $11.65 and a max of $19.04, with a 45.8% ROI and bullish sentiment.
The forecast indicates neutral sentiment in 2026 with an average price of $7.99, followed by rising averages and bullish sentiment in later years (e.g., 2031–2050), with ROIs up to 561% in 2050. These are estimates, not guarantees.
Yes—the 2050 forecast max is $119.16, which exceeds $100, indicating potential upside by 2050.
The 30-day range is $6.00 to $10.63.
Current price is $7.99 and market cap is $585.43M.
Candel Therapeutics, Inc. Community Discussion
0Share your Candel Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.